Anidulafungin: is it a promising option in the treatment of pediatric invasive fungal infections?

References

• Blyth CC, Chen SC, Slavin MA et al. Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. Pediatrics123, 1360–1368 (2009).
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Prasad PA, Localio AR et al. Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin. Infect. Dis.51, 38–45 (2010).
   PubMed Web of Science ®Google Scholar
• Neu N, Malik M, Lunding A et al. Epidemiology of candidemia at a Children’s hospital, 2002 to 2006. Pediatr. Infect. Dis. J.28, 806–809 (2009).
   PubMed Web of Science ®Google Scholar
• Charlier C, Hart E, Lefort A et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J. Antimicrob. Chemother.57, 384–410 (2006).
   PubMed Web of Science ®Google Scholar
• Pannaraj PS, Walsh TJ, Baker CJ. Advances in antifungal therapy. Pediatr. Infect. Dis. J.24, 921–922 (2005).
   PubMedGoogle Scholar
• Lass-Flörl C. Invasive fungal infections in pediatric patients: a review focusing on antifungal therapy. Expert Rev. Anti Infect. Ther.8, 127–135 (2010).
   PubMed Web of Science ®Google Scholar
• Messer SA, Jones RN, Moet GJ, Kirby JT, Castanheira M. Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008). J. Clin. Microbiol.48, 2984–2987 (2010).
   PubMed Web of Science ®Google Scholar
• Messer SA, Moet GJ, Kirby JT, Jones RN. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J. Clin. Microbiol.47, 1942–1946 (2009).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Hollis R, Goldstein BP, Messer S, Diekema D, Henkel T. In vitro activity of anidulafungin and other agents against esophageal candidiasis-associated isolates from a Phase 3 clinical trial. J. Clin. Microbiol.48, 2613–2614 (2010).
   PubMedGoogle Scholar
• Hof H, Dietz A. Antifungal activity of anidulafungin, a product of Aspergillus nidulans, against Aspergillus nidulans. Int. J. Antimicrob. Agents33, 285–286 (2009).
   PubMedGoogle Scholar
• Denning DW. Echinocandin antifungal drugs. Lancet362, 1142–1151 (2003).
   PubMed Web of Science ®Google Scholar
• Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, Ostrosky-Zeichner L. In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob. Agents Chemother.48, 1912–1915 (2004).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J. Clin. Microbiol.43, 5425–5427 (2005).
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol.36, 198–202 (1998).
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Messer SA, Boyken LB et al.In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. J. Clin. Microbiol.47, 3170–3177 (2009).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Ostrosky-Zeichner L et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol.46, 2620–2629 (2008).
   PubMed Web of Science ®Google Scholar
• Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat.10, 121–130 (2007).
   PubMed Web of Science ®Google Scholar
• Garcia-Effron G, Chua DJ, Tomada JR et al. Novel FKS mutations associated with echinocandin resistance in Candida species. Antimicrob. Agents Chemother.54, 2225–2227 (2010).
   PubMed Web of Science ®Google Scholar
• Garcia-Effron G, Lee S, Park S, Cleary JD, Perlin DS. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-β-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother.53, 3690–3699 (2009).
   PubMed Web of Science ®Google Scholar
• Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J. Clin. Pharmacol.44, 590–598 (2004).
   PubMed Web of Science ®Google Scholar
• Nguyen KT, Ta P, Hoang BT et al. Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates. Antimicrob. Agents Chemother.53, 3347–3352 (2009).
   PubMed Web of Science ®Google Scholar
• Benjamin DK Jr, Driscoll T, Seibel NL et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob. Agents Chemother.50, 632–638 (2006).
   PubMed Web of Science ®Google Scholar
• Dowell JA, Stogniew M, Krause D, Damle B. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J. Clin. Pharmacol.47, 461–470 (2007).
   PubMed Web of Science ®Google Scholar
• Damle B, Stogniew M, Dowell J. Pharmacokinetics and tissue distribution of anidulafungin in rats. Antimicrob. Agents Chemother.52, 2673–2676 (2008).
   PubMed Web of Science ®Google Scholar
• Perkhofer S, Lass-Flörl C. Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination. Expert Opin. Investig. Drugs18, 1393–1404 (2009).
   PubMed Web of Science ®Google Scholar
• Damle BD, Dowell JA, Walsky RL, Weber GL, Stogniew M, Inskeep PB. In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. Antimicrob. Agents Chemother.53, 1149–1156 (2009).
   PubMed Web of Science ®Google Scholar
• Krause DS, Simjee AE, van Rensburg C et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin. Infect. Dis.39, 770–775 (2004).
   PubMed Web of Science ®Google Scholar
• Reboli AC, Rotstein C, Pappas PG et al.; Anidulafungin Study Group. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med.356, 2472–2482 (2007).
   PubMed Web of Science ®Google Scholar
• Pfizer, Inc. Final package insert for ERAXIS (anidulafungin) for injection. NY, USA (2006).
   Google Scholar
• Dowell JA, Stogniew M, Krause D, Henkel T, Weston IE. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J. Clin. Pharmacol.45, 227–233 (2005).
   PubMed Web of Science ®Google Scholar
• Dowell JA, Schranz J, Baruch A, Foster G. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J. Clin. Pharmacol.45, 1373–1382 (2005).
   PubMed Web of Science ®Google Scholar
• Dowell JA, Stogniew M, Krause D, Henkel T, Damle B. Lack of pharmacokinetic interaction between anidulafungin and tacrolimus. J. Clin. Pharmacol.47, 305–314 (2007).
   PubMed Web of Science ®Google Scholar
• Eschenauer G, Depestel DD, Carver PL. Comparison of echinocandin antifungals. Ther. Clin. Risk Manag.3, 71–97 (2007).
   PubMedGoogle Scholar
• Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin. Infect. Dis.43, 215–222 (2006).
   PubMed Web of Science ®Google Scholar
• Philip A, Odabasi Z, Rodriguez J et al.In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob. Agents Chemother.49, 3572–3574 (2005).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Boyken L et al. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrob. Agents Chemother.49, 4795–4797 (2005).
   PubMed Web of Science ®Google Scholar
• Krause DS, Reinhardt J, Vazquez JA et al.; Anidulafungin Invasive Candidiasis Study Group. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob. Agents Chemother.48, 2021–2024 (2004).
   PubMed Web of Science ®Google Scholar
• Kett DH, Cubillos GF. Anidulafungin in the treatment of patients with invasive candidiasis. Int. J. Antimicrob. Agents32, 99–102 (2008).
   Google Scholar
• Cheung C, Guo Y, Gialanella P, Feldmesser M. Development of candidemia on caspofungin therapy: a case report. Infection34, 345–348 (2006).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Gibbs DL et al.; Global Antifungal Surveillance Group. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J. Clin. Microbiol.46, 842–849 (2008).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Boyken L, Hollis RJ et al.In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol.46, 150–156 (2008).
   PubMed Web of Science ®Google Scholar
• Sarvikivi E, Lyytikäinen O, Soll DR et al. Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J. Clin. Microbiol.43, 2729–2735 (2005).
   PubMed Web of Science ®Google Scholar
• van Asbeck E, Clemons KV, Martinez M, Tong AJ, Stevens DA. Significant differences in drug susceptibility among species in the Candida parapsilosis group. Diagn. Microbiol. Infect. Dis.62, 106–109 (2008).
   PubMed Web of Science ®Google Scholar
• Ghannoum MA, Chen A, Buhari M et al. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit. Clin. Microbiol. Infect.15, 274–279 (2009).
   PubMed Web of Science ®Google Scholar
• Moudgal V, Little T, Boikov D, Vazquez JA. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob. Agents Chemother.49, 767–769 (2005).
   PubMed Web of Science ®Google Scholar
• Silva AP, Miranda IM, Lisboa C, Pina-Vaz C, Rodrigues AG. Prevalence, distribution, and antifungal susceptibility profiles of Candida parapsilosis, C. orthopsilosis, and C. metapsilosis in a tertiary care hospital. J. Clin. Microbiol.47, 2392–2397 (2009).
   PubMed Web of Science ®Google Scholar
• de Toro M, Torres MJ, Maite R, Aznar J. Characterization of Candida parapsilosis complex isolates. Clin. Microbiol. Infect.17(3), 418–424 (2010).
   Google Scholar
• Tumbarello M, Posteraro B, Trecarichi EM et al. Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J. Clin. Microbiol.45, 1843–1850 (2007).
   PubMed Web of Science ®Google Scholar
• Jacobson MJ, Piper KE, Nguyen G, Steckelberg JM, Patel R. In vitro activity of anidulafungin against Candida albicans biofilms. Antimicrob. Agents Chemother.52, 2242–2243 (2008).
   PubMed Web of Science ®Google Scholar
• Katragkou A, Chatzimoschou A, Simitsopoulou M et al. Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms. Antimicrob. Agents Chemother.52, 357–360 (2008).
   PubMed Web of Science ®Google Scholar
• Kucharíková S, Tournu H, Holtappels M, Van Dijck P, Lagrou K. In vivo efficacy of anidulafungin against Candida albicans mature biofilms in a novel rat model of catheter-associated candidiasis. Antimicrob. Agents Chemother.54(10), 4474–4475 (2010).
   PubMed Web of Science ®Google Scholar
• Sobel JD, Revankar SG. Echinocandins – first-choice or first-line therapy for invasive candidiasis? N. Engl. J. Med.356, 2525–2526 (2007).
   PubMedGoogle Scholar
• Pappas G, Ierodiakonou V, Falagas ME. Lost in translation: differences in antimicrobial indication approval policies between the United States and Europe. Clin. Ther.31, 1595–1603 (2009).
   PubMedGoogle Scholar
• Kang CI, Rouse MS, Mandrekar JN, Steckelberg JM, Patel R. Anidulafungin treatment of Candida central nervous system infection in a murine model. Antimicrob. Agents Chemother.53, 3576–3578 (2009).
   PubMed Web of Science ®Google Scholar
• Falcone M, Accarpio F, Venditti M et al. Septic bilateral pulmonary candidiasis successfully treated with anidulafungin therapy in two patients with peritoneal carcinomatosis. J. Antimicrob. Chemother.65(10), 2266–2267 (2010).
   PubMed Web of Science ®Google Scholar
• Krause DS, Simjee AE, van Rensburg C et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin. Infect. Dis.39, 770–775 (2004).
   PubMed Web of Science ®Google Scholar
• Vazquez JA, Schranz JA, Clark K, Goldstein BP, Reboli A, Fichtenbaum C. A Phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis. J. Acquir. Immune Defic. Syndr.48, 304–309 (2008).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Hollis R, Goldstein BP, Messer S, Diekema D, Henkel T. In vitro activity of anidulafungin and other agents against esophageal candidiasis-associated isolates from a Phase 3 clinical trial. J. Clin. Microbiol.48, 2613–2614 (2010).
   PubMedGoogle Scholar
• Andes D, Diekema DJ, Pfaller MA et al.In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model. Antimicrob. Agents Chemother.52, 539–550 (2008).
   PubMed Web of Science ®Google Scholar
• Krishnan-Natesan S, Manavathu EK, Cutright JL, Chandrasekar PH. Efficacy of anidulafungin, caspofungin and fluconazole in the early phase of infection in a neutropenic murine invasive candidiasis model. Int. J. Antimicrob. Agents36, 33–36 (2010).
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Groll AH et al. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother.42, 2898–2905 (1998).
   PubMed Web of Science ®Google Scholar
• Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob. Agents Chemother.52, 321–328 (2008).
   PubMed Web of Science ®Google Scholar
• Spreghini E, Orlando F, Santinelli A et al. Anidulafungin in combination with amphotericin B against Aspergillus fumigatus. Antimicrob. Agents Chemother.53, 4035–4039 (2009).
   PubMed Web of Science ®Google Scholar
• Perkhofer S, Jost D, Dierich MP, Lass-Flörl C. Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions. Antimicrob. Agents Chemother.52, 1873–1875 (2008).
   PubMed Web of Science ®Google Scholar
• van de Sande WW, Mathot RA, ten Kate MT et al. Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin. Antimicrob. Agents Chemother.53, 2005–2013 (2009).
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Hope WW et al. Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose-dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis. Antimicrob. Agents Chemother.53, 2382–2391 (2009).
   PubMed Web of Science ®Google Scholar